CorMedix (CRMD) Q4 2025 earnings review
Record Run Meets a Looming Reimbursement Cliff
CorMedix capped off a transformational 2025 with Q4 revenue of $128.6M, driven by DefenCath's strong commercial ramp and the first full quarter of Melinta portfolio contributions. Operational profitability is accelerating, with Q4 Adjusted EBITDA hitting $77.2M. However, despite a new $75M share repurchase authorization and flawless near-term execution, a massive red flag waves in the FY26 guidance. The FY26 revenue midpoint of $310M implies a steep 22% deceleration from the FY25 pro forma run rate of $401.3M. This drop is tied directly to the July 2026 expiration of DefenCath's TDAPA reimbursement, forcing management to aggressively pivot the narrative toward pipeline assets to bridge the impending revenue gap.
🐂 Bull Case
The Melinta acquisition is already paying off, contributing $37.4M in Q4. It diversifies the company away from a single product and dramatically boosts cash generation, funding the newly announced $75M buyback.
DefenCath generated $91.2M in Q4 alone, proving exceptional market fit in outpatient dialysis. Current adoption rates with large dialysis organizations (LDOs) have significantly outpaced initial expectations.
🐻 Bear Case
On July 1, 2026, DefenCath transitions off TDAPA reimbursement. Management explicitly warned of a 'significant decline in reimbursement and net pricing' for H2 2026, instantly derailing the company's current top-line growth trajectory.
Pro forma FY25 revenue (including a full year of Melinta) was $401.3M. Guidance for FY26 is $300-$320M. This implies the business will actually shrink YoY in 2026 as pricing pressures take hold.
⚖️ Verdict: ⚪
Neutral. CorMedix is executing perfectly on its commercial launch and M&A integration today, but the guaranteed mechanical reduction in H2 2026 pricing creates an unavoidable earnings air pocket that makes the near-term stock trajectory highly volatile.
Key Themes
The July 2026 Reimbursement Cliff
The entire CorMedix investment thesis currently hinges on H2 2026. DefenCath's TDAPA reimbursement transitions to a post-TDAPA Add-On Adjustment on July 1, 2026. CMS's methodology is expected to cause a significant reduction in net pricing for Q3 and Q4 2026. While the company estimates the 2027 adjustment will rebound to be 3x-5x higher than H2 2026, the back half of this year will see severe top-line compression.
Melinta Acquisition Diversification
The Melinta portfolio (MINOCIN, VABOMERE, ORBACTIV, etc.) provided its first full quarter of results, contributing $37.4M. This diversifies the company's revenue stream away from hemodialysis and provides a crucial, stable baseline to help absorb the H2 2026 DefenCath pricing shock.
Pipeline Pivot: Rezzayo and TPN
Knowing the TDAPA cliff is coming, management is aggressively redirecting attention to clinical catalysts. Topline data for the Phase 3 ReSPECT study of Rezzayo (prophylaxis of invasive fungal infections in BMT patients) is due in Q2 2026. Management views this as a $2B+ total addressable market. Meanwhile, the DefenCath Phase 3 study in Total Parenteral Nutrition (TPN) targets completion in H1 2027.
Tax Expense Volatility Masking Operating Strength
Net income fell sharply from $108.6M in Q3 to $14.0M in Q4. However, this was largely an accounting distortion. Q3 included a massive $59.7M tax benefit, while Q4 included a $42.4M tax expense related to the utilization of deferred tax assets. Investors must focus on Adjusted EBITDA ($77.2M in Q4) to understand true cash-generating power.
Other KPIs
Accelerating. Up 182% YoY from $17.1M. This $31.1M increase was driven primarily by the first full quarter of Melinta operating expenses, alongside $4.1M in non-recurring severance and integration costs. R&D spending also grew to support the DefenCath TPN Phase 3 study.
Stable. The company maintained a highly liquid balance sheet (excluding restricted cash) at year-end, which gave the Board confidence to authorize a new $75 million share repurchase program. This buyback provides downside support during the anticipated H2 2026 volatility.
Guidance
Reversing. While this represents flat growth compared to FY25 GAAP revenue ($311.7M), it is a drastic 22% deceleration compared to the FY25 Pro Forma revenue of $401.3M. This guidance bakes in the severe pricing compression expected for DefenCath when TDAPA ends on July 1, 2026.
Decelerating. With Q4 2025 alone generating $77.2M in Adjusted EBITDA, a full-year 2026 guide of $112.5M at the midpoint implies that profitability will crater in the second half of the year as DefenCath margins compress. The company is leaning on $35M+ in annualized Melinta synergies to defend the bottom line.
Key Questions
Bridging the Pro Forma Gap
Your FY25 pro forma revenue was $401 million, but your FY26 guidance is $310 million at the midpoint. Can you precisely quantify how much of this $90 million gap is attributed to the H2 DefenCath TDAPA pricing cliff versus base Melinta portfolio dynamics?
Post-TDAPA Contracting Strategy
With the expected pricing drop in Q3/Q4, how are negotiations progressing with Medicare Advantage plans? At what point in 2026 will you have definitive contracts signed to provide investors visibility into the 2027 rebound?
Capital Allocation Priority
You announced a $75 million share repurchase program, but you also have upcoming data for Rezzayo and a pending Phase 3 for TPN. How do you balance this buyback against the potential need to acquire additional commercial-stage assets to plug the H2 2026 revenue hole?